<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021125</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-CH03</org_study_id>
    <secondary_id>CDR0000068750</secondary_id>
    <secondary_id>EU-20121</secondary_id>
    <secondary_id>ISRCTN62576956</secondary_id>
    <nct_id>NCT00021125</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Head and Neck Cancer</brief_title>
  <official_title>A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet&#xD;
      known which regimen of radiation therapy is more effective for head and neck cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of&#xD;
      radiation therapy in treating patients who have head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare adjuvant continuous hyperfractionated accelerated radiotherapy vs conventional&#xD;
           radiotherapy, in terms of preventing disease recurrence, in patients with head and neck&#xD;
           cancer.&#xD;
&#xD;
        -  Compare the early and late toxic effects of these treatments in this patient population.&#xD;
&#xD;
        -  Compare disease-free and overall survival of patients receiving these treatments.&#xD;
&#xD;
        -  Assess quality of life in patients receiving these treatments.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo radiotherapy 3 times daily, with an interval of at least 6 hours&#xD;
           between any 2 treatments, 5 days a week, for just over 2 weeks, for a total of 13-14&#xD;
           treatment days.&#xD;
&#xD;
        -  Arm II: Patients undergo radiotherapy daily, 5 days a week, for 6-6.5 weeks. Quality of&#xD;
           life is assessed at baseline and then annually for 5 years.&#xD;
&#xD;
      Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 460 patients (230 per arm) will be accrued for this study&#xD;
      within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Time to local recurrence</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity and toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by EORTC Quality of life Questionnaire for Head and Neck Cancer</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck including, but&#xD;
             not limited to, the following:&#xD;
&#xD;
               -  Oral cavity&#xD;
&#xD;
               -  Oropharynx&#xD;
&#xD;
               -  Hypopharynx&#xD;
&#xD;
               -  Larynx&#xD;
&#xD;
               -  Nasal sinuses&#xD;
&#xD;
               -  Skin&#xD;
&#xD;
          -  Undergone curative surgery within the past 70 days&#xD;
&#xD;
               -  All macroscopic disease removed&#xD;
&#xD;
          -  At high or intermediate risk of recurrence&#xD;
&#xD;
               -  No low risk of recurrence&#xD;
&#xD;
          -  No evidence of distant metastases&#xD;
&#xD;
          -  Considered treatable by radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy that would preclude study participation&#xD;
&#xD;
          -  No other uncontrolled medical illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. I. Saunders, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mount Vernon Cancer Centre at Mount Vernon Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>squamous cell carcinoma of the skin</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage I salivary gland cancer</keyword>
  <keyword>stage II salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

